A new paraneoplastic biomarker + Drug pricing controversies: "Evergreening" in pharma
In the first segment, Dr. Stacey Clardy talks with Dr. Anastasia Zekeridou about her paper on Phosphodiesterase 10A-IgG, a novel biomarker of paraneoplastic neurological autoimmunity. In the second pa...
19 Elo 201927min
Impulse control and RBD in PD + CRISPR babies
In the first segment, Dr. Jason Crowell talks with Dr. Michele Hu and Dr. David Okai about their longitudinal study of the severity of impulse control disorders in Parkinson disease and RBD. In the se...
12 Elo 201926min
GAD Deposition in MS MRIs + Cervical Dystonia Network Localization
In the first segment, Dr. Stacey Clardy talks with Dr. Robert Zivadinov about cumulative gadodiamide administration leading to brain gadolinium deposition in early MS. In the second part of the podcas...
5 Elo 201923min
More Neurology Minute Highlights (Delayed Recall August 2019)
This month's Delayed Recall highlights more interviews from our new podcast offering, Neurology Minute. In 2019, Neurology launched a new podcast perfect for Alexa and other similar devices. This epis...
1 Elo 201933min
CDC's Guideline on Pediatric Mild Traumatic Brain Injury: Recommendations for Neurologists
In the first segment, Dr. Kristen Heinan talks with Dr. Barbara Weissman about her Neurology: Clinical Practice paper on recommendations for neurologists on the CDC's Guideline on Pediatric Mild Traum...
29 Heinä 201923min
Determining clinically meaningful decline in preclinical Alzheimer disease
In the first segment, Dr. Gregory Day talks with Dr. Philip Insel about his paper on determining clinically meaningful decline in preclinical Alzheimer disease. In the second part of the podcast, Dr. ...
22 Heinä 201921min
SUDEP in the North American SUDEP Registry: The full spectrum of epilepsies
In the first segment, Dr. Halley Alexander talks with Dr. Orrin Devinsky about his paper on the full spectrum of epilepsies and the North American SUDEP Registry. In the second part of the podcast, Dr...
15 Heinä 201924min
Use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease
In the first segment, Dr. Jeffrey Ratliff talks with Dr. Franziska Hopfner about her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. In the second par...
8 Heinä 201923min
